Human cathelicidin, hCAP-18, is processed to the antimicrobial peptide LL-37 by extracellular cleavage with proteinase 3

Ole E. Sørensen, Per Follin, Anders H. Johnsen, Jero Calafat, G. Sandra Tjabringa, Pieter S. Hiemstra, and Niels Borregaard

Cathelicidins are a family of antimicrobial proteins found in the peroxidase-negative granules of neutrophils. The known biologic functions reside in the C-terminus, which must be cleaved from the holoprotein to become active. Bovine and porcine cathelicidins are cleaved by elastase from the azurophil granules to yield the active antimicrobial peptides. The aim of this study was to identify the physiological setting for cleavage of the only human cathelicidin, hCAP-18, to liberate the antibacterial and cytotoxic peptide LL-37 and to identify the protease responsible for this cleavage. Immunoelectron microscopy demonstrated that both hCAP-18 and azurophil granule proteins were present in the phagolysosome. Immunoblotting revealed no detectable cleavage of hCAP-18 in cells after phagocytosis. In contrast, hCAP-18 was cleaved to generate LL-37 in exocytosed material. Of the 3 known serine proteases from azurophil granules, proteinase 3 was solely responsible for cleavage of hCAP-18 after exocytosis. This is the first detailed study describing the generation of a human antimicrobial peptide from a promicrobial protein, and it demonstrates that the generation of active antimicrobial peptides from common proproteins occurs differently in related species. (Blood. 2001; 97:3951-3959)
with recombinant hCAP-18. Monoclonal antibodies toward LL-37 were generated by immunization of mice with glutaraldehyde–cross-linked synthetic LL-37. Monoclonal antibodies were obtained using conventional hybridoma technology (S.T. et al, manuscript in preparation).

Anti–proteinase 3 antibodies and proteinase 3 were generously provided by Jörgen Wieslander (Wieslab AB, Lund, Sweden). Human leukocyte elastase, cathespin G, and SLPI were purchased from ICN Biomedicals (Costa Mesa, CA). Antielastase antibodies were from Biodesign International (Kennebunk, ME). All other antibodies were purchased from DAKO A/S (Glostrup, Denmark).

### Sodium dodecyl sulfate–polyacrylamide gel electrophoresis and immunoblotting

Sodium dodecyl sulfate–polyacrylamide gel electrophoresis (SDS-PAGE) and immunoblotting were performed with Mini-Protein 3 Cells and Mini Trans-Blot Electrotransfer Transfer Cells according to the instructions given by the manufacturer (Bio-Rad, Hercules, CA). For immunoblotting, polyvinylidene difluoride (PVDF) membranes (Millipore, Bedford, MA) were blocked for 1 hour with 5% skimmed milk in phosphate-buffered saline (PBS) after the transfer of proteins from the 14% polyacrylamide gels. For visualization of hCAP-18, the PVDF membranes were incubated overnight with primary antibodies. The next day, membranes were incubated for 2 hours with horseradish peroxidase–conjugated secondary antibodies (DAKO) and visualized by diaminobenzidine–metal concentrate.

### Isolation of neutrophils from peripheral blood

Human neutrophils were isolated from freshly prepared buffy coats or from healthy donors as described. Briefly, after sedimentation with 2% Dextran T-500 (Amersham Pharmacia Biotech, Uppsala, Sweden) in isotonic NaCl, the leukocyte-rich supernatant was pelleted and resuspended in saline for subsequent centrifugation on Lymphoprep (Nycomed Pharma A/S, Oslo, Norway) at 400 g for 30 minutes for the removal of lymphocytes and monocytes. Remaining erythrocytes were lysed in ice-cold de-ionized water for 30 seconds. Tonicity was restored by the addition of 1 vol of 1.8% NaCl. Cells were washed once and resuspended in the desired buffer. With the exception of Dextran sedimentation, all steps were carried out at 4°C.

### Isolation of exudate neutrophils from skin window chambers

Exudate neutrophils were isolated from skin window chambers placed on the forearms of healthy human donors, as described. Briefly, chambers with 3.06 mL wells covering the lesions were used. They were filled with autologous serum and incubated for 18 hours. Chambers were then emptied, washed, and filled with fresh autologous citrated plasma. Neutrophils were allowed to accumulate in the chambers for 7 hours. Cells were harvested, pelleted by centrifugation, washed once, and resuspended in the desired buffer. More than 95% of the harvested cells were neutrophils.

### Purification of hCAP-18 from neutrophils

Neutrophils were disrupted by nitrogen cavitation after the addition of 5 mM di-isopropyl fluorophosphate (Sigma, St Louis, MO). Postnuclear supernatants were loaded on 2-layer gradients (1.05/1.12 g/mL) of Percoll (Amersham Pharmacia Biotech). This resulted in 3 visible bands. Starting at the bottom, the bands are designated the α-band, containing azurophil granules; the β-band, containing specific and gelatinase granules; and the γ-band, containing plasma membranes and secretory vesicles.

The β-band containing specific granules was harvested manually, and Percoll was removed by ultracentrifugation. Isolated granules were treated with 5 mM di-isopropyl fluorophosphate. Granules were lysed in PBS containing 1% Triton X-100 (Boehringer Ingelheim, Heidelberg, Germany), 1 mM phenylmethylsulfonyl fluoride (Sigma), 100 kallikrein inhibitory U/mL aprotinin (Bayer, Leverkusen, Germany), 100 μg/mL leupeptin (Sigma), and 1 mM EDTA (Sigma). Membranes were pelleted by centrifugation, and the supernatant containing the specific granule proteins was frozen at −80°C until further use.

Isolated specific granule proteins were subjected to cation exchange chromatography on a MonoS column using AKTA-FPLC (Amersham Pharmacia Biotech AB). Most of the bound material was eluted with 1 M NaCl, 9.5 mM phosphate, pH 7.4. hCAP-18 was subsequently eluted with 10 mM NaOH, 140 mM NaCl. Immunoblotting with anti–hCAP-18 antibodies of the eluted hCAP-18 showed one band of the appropriate molecular mass.

For cleavage experiments with purified proteases and amino acid sequence analysis, hCAP-18 was purified from specific granules on an anti–hCAP-18 antibody column as previously described.

### Isolation of azurophil granule proteins from neutrophils

Neutrophils were subjected to nitrogen cavitation and subcellular fractionation as described above but without protease inhibitors. After the removal of Percoll from the α-band containing the azurophil granules, the granules were freeze-thawed 5 times in 1 M NaCl. Membranes were pelleted by ultracentrifugation, and the supernatant containing the matrix proteins of azurophil granules was harvested and stored at −80°C until further use.

### Exocytosis and phagocytosis experiments

Isolated neutrophils, freshly prepared from peripheral blood or skin windows of healthy donors, were resuspended in Krebs Ringer phosphate (10 mM NaH2PO4/Na2HPO4, 130 mM NaCl, 5 mM KCl, 0.95 mM CaCl2, 5 mM glucose) at a concentration of 107 cell/mL. Cells were preincubated at 37°C for 5 minutes and then stimulated with 1 μM ionomycin (Calbiochem, La Jolla, CA), 10−8 M formylmethionyleucylphenylalanine (fMLP; Sigma), or IgG-coated latex beads for 20 minutes at 37°C. Stimulation was stopped by the addition of 2 vol ice-cold buffer and subsequent pelleting by centrifugation. The supernatant containing the exocytosed material was analyzed by enzyme-linked immunosorbent assay (ELISA) or immunoblotting.

After stimulation, aliquots of the cells were either used for quantification of granule proteins by ELISA or resuspended to a concentration of 1 × 106 cells/mL and precipitated with 5% trichloroacetic acid (final concentration). The pellet was washed 5 times with acetone and resuspended in Laemml sample buffer for analysis by SDS-PAGE and immunoblotting. Remaining cells were fixed for electron microscopy.

### Preparation of exocytosed material for cleavage experiments

Neutrophils (3 × 107 cells/mL) were stimulated to exocytosis by 1 μM ionomycin as described above. After stimulation, the cells were placed on ice for 10 minutes and subsequently pelleted by centrifugation. The supernatant was frozen at −20°C until further experiments. Endogenous hCAP-18 was subsequently removed from the exocytosed material by affinity chromatography on an anti–hCAP-18 antibody column. After affinity chromatography, the exocytosed material was immediately used as a source of proteases for cleavage of hCAP-18.
Cleavage experiments

Intact hCAP-18 isolated from specific granules by ÄKTA-FPLC was incubated with exocytosed material from neutrophils, azurophil granule proteins, or purified proteases at 37°C for 30 minutes. The sample was subsequently boiled in Laemmli sample buffer and run on a SDS-PAGE followed by immunoblotting.

Amino acid sequence analysis

Amino acid sequence was analyzed on the PVDF-blotted protein in a 494 A Procise Protein Sequencer (PerkinElmer, Palo Alto, CA) using the blot cartridge and PVDF cycles. All reagents and solvents were supplied by PerkinElmer.

Immunoprecipitation

Antibodies against elastase, cathepsin G, proteinase 3, α₁-h-trypsin, and normal rabbit immunoglobulins were incubated with Protein A Sepharose (Pharmacia) for 30 minutes at room temperature in PBS (pH 7) with 0.5 M NaCl. Sepharose particles were subsequently washed 7 times in PBS with 0.5 M NaCl to remove unbound antibodies; this was followed by incubation with exocytosed material at 4°C for 2 hours. Sepharose particles were pelleted by centrifugation. Supernatants were aspirated and immediately used for cleavage experiments.

Immunoelectron microscopy

Cells were fixed in a mixture of 0.5% glutaraldehyde and 4% paraformaldehyde in 0.1 M phosphate buffer (pH 7.2) for 2 hours at room temperature. They were then stored in 4% paraformaldehyde at 4°C until they were processed for ultrathin cryosectioning. For single labeling, cryosections were incubated with rabbit anti–hCAP-18; this was followed by 10-nm protein A–conjugated colloidal gold. For double labeling, the sections were first incubated with mouse monoclonal anti-human myeloperoxidase (CLB; Amsterdam, The Netherlands) followed by rabbit anti-mouse IgG and 5-nm protein A gold, and then they were treated with 1% glutaraldehyde for 10 minutes to prevent interference between the different antibody gold complexes in the sections. They were further incubated with rabbit anti–hCAP-18 followed by 10-nm protein A–conjugated colloidal gold (5-nm and 10-nm protein A–conjugated gold; EM Laboratory, Utrecht University, The Netherlands). After immunolabeling, the cryosections were embedded in a mixture of methylecellulose and uranyl acetate and examined with a Philips CM 10 electron microscope (Eindhoven, The Netherlands). For controls, the primary antibody was replaced by a nonrelevant murine or rabbit antiserum, respectively.

Quantitation of proteins

Myeloperoxidase, hCAP-18, and gelatinase were measured by ELISA as previously described, α₁-antitrypsin, elastase, cathepsin G, and proteinase 3 were quantitated by semiquantitative ELISA. Anti–proteinase 3 antibodies were previously described. Anti–proteinase 3 antibodies were previously described. 29,37,38 

Samples were diluted in 50 mM Na₂CO₃/NaHCO₃ buffer, pH 9.6, and incubated in 96-well flat-bottom immunoplates (Nunc, Roskilde, Denmark) overnight at room temperature. Unspecific binding was blocked by incubation with 200 µL/well dilution buffer (0.5 M NaCl, 3 mM KCl, 8 mM Na₂HPO₄/KH₂PO₄, 1% BSA (Sigma), 1% Triton X-100, pH 7.2) for 1 hour. Biotinylated antibodies against the above-mentioned antigens were diluted in dilution buffer and incubated for 1 hour. Horseradish peroxidase–labeled avidin (DAKO) was diluted 1500-fold in dilution buffer and incubated for 1 hour. Plates were washed 3 times in washing buffer (0.5 M NaCl, 3 mM KCl, 8 mM Na₂HPO₄/KH₂PO₄, 1% Triton X-100, pH 7.2) for 1 hour. Plates were washed once in substrate buffer (0.1 M sodium phosphate, 0.1 M citric acid, pH 5.0) before color development and then incubated with substrate buffer containing 0.04% o-phenyl-diamine (Kem-En-Tec, Copenhagen, Denmark) and 0.03% H₂O₂. Unless otherwise stated, 100 µL was added to each well at each incubation step. Color development was stopped by the addition of 100 µL 1 M H₂SO₄, absorbance measured at 492 nm in a Multiscan Plus ELISA Reader (Labsystems, Helsinki, Finland). A standard curve of serial dilutions of exocytosed material from neutrophils was used.

Activity of exocytosed elastase and cathepsin G

Freshly prepared exocytosed material from ionomycin-stimulated neutrophils (5 × 10⁵ cells/mL) was incubated with specific nitroanilide substrates for elastase (N-methoxysuccinyl-ala-ala-pro-val p-nitroanilide; Sigma) or cathepsin G (N-methoxysuccinyl-ala-ala-pro-met p-nitroanilid; Sigma). The amount of free nitroanilide was quantitated by measurement of the absorbance at 410 nm.

Preparation of lipoprotein-bound hCAP-18

Purified hCAP-18 was incubated with plasma for 2 hours at 37°C. Plasma was then subjected to molecular-sieve chromatography on a Superose 12 column using ÄKTA-FPLC. The high molecular peak fraction of hCAP-18 containing lipoprotein-bound hCAP-18, as previously described, was used for further cleavage experiments.

Results

To investigate whether hCAP-18 is cleaved in the phagocytic vacuole, neutrophils from peripheral blood and from skin windows
were isolated and stimulated to phagocytosis by immunoglobulin-coated latex beads. After phagocytosis, the cells were fixed for electron microscopy or pelleted and resuspended in 0.9% NaCl followed by TCA-precipitation. Immuneelectron microscopy demonstrated that the PMNs had phagocytosed the latex beads and that hCAP-18 was found both in the specific granules and in the phagolysosomes (Figure 2A). In single sections from 106 exudate neutrophils from skin windows, phagolysosomes were found in 103 cells. In blood neutrophils, phagolysosomes were found in only 1 of 103 cells. Double-immunogold labeling of hCAP-18 and myeloperoxidase was performed to demonstrate that both azurophil and specific granules had fused with the phagolysosome (Figure 2B). Thirty-three phagolysosomes were examined for the presence of myeloperoxidase and hCAP-18 in 7 sections from different exudate neutrophils from skin windows. Twenty-seven phagolysosomes were labeled with both myeloperoxidase and hCAP-18. Three were labeled only for myeloperoxidase and 3 only for hCAP-18. Because only one section was examined for each phagolysosome, it cannot be ruled out that those positive only for one marker would have been positive for both markers in another section of the same phagolysosome. Thus, most phagolysosomes contained both hCAP-18 and azurophil granule proteins. TCA precipitates from neutrophils after phagocytosis were analyzed by SDS-PAGE, and then they were immunoblotted with anti-hCAP-18 antibodies. Despite the “priming” of phagocytosis in cells from skin windows, no intracellular cleavage of hCAP-18 was found after phagocytosis of latex beads (Figure 3A, lane c). The same result was found in blood neutrophils (Figure 3B, lane c). As expected, unperturbed cells and cells stimulated to exocytosis by fMLP and ionomycin showed no cleavage of hCAP-18 (see Figure 3A-B, lanes a, b, and d). Control experiments ascertained that TCA-precipitation did not influence the detection of the low-molecular-weight fragments by immunoblotting and that the cleavage of hCAP-18 by serine proteases from azurophil granules was not inhibited by immunoglobulin-coated latex beads (data not shown). To validate that the lack of detectable cleavage of hCAP-18 in cell lysates after phagocytosis did not result from insufficient degranulation of hCAP-18 into the phagocytic vacuole, the immunogold-labeled hCAP-18 was counted in granules and phagolysosomes. More than 50% of the labeled hCAP-18 was present in the phagolysosome in the neutrophils harvested from skin windows and stimulated to phagocytosis by latex beads (Table 1). Although this was a semiquantitative measure of degranulation into the phagolysosome, it demonstrated that a substantial part of the hCAP-18 in these cells was localized to the phagolysosome.

Phagocytosis experiments with serum-treated zymosan particles performed with neutrophils from skin windows and peripheral blood gave similar results (data not shown). Thus, cleavage of hCAP-18 was not detectable in the phagocytic vacuole.

**Exocytosis experiments**

Neutrophils from peripheral blood or from skin chamber windows were stimulated to exocytosis by different secretagogues (Table 2). The exocytosed material was analyzed by immunoblotting with anti-hCAP-18 antibodies. Significant cleavage of hCAP-18 was only detected in the exocytosed material from ionomycin-stimulated neutrophils (Figure 4A-B, lane d). We have previously demonstrated that the 14-kd fragment of hCAP-18 in the exocytosed material is cathelin and that the 4-kd fragment represents the noncathelin C-terminus of hCAP-18.24 The absolute concentrations of azurophil granule proteins were highest in the exocytosed material from ionomycin-stimulated cells (in particular from blood neutrophils) (Table 2). The absolute concentration of azurophil markers correlated with the degree to which hCAP-18 was cleaved. This indicates that the concentration of protease in the medium determines whether hCAP-18 is cleaved. Prolonged incubation (1 hour) of neutrophils did not give rise to further cleavage of hCAP-18 in the exocytosed material (data not shown). When neutrophils were stimulated by fMLP at a cell concentration of 3 x 10^6 cells/mL, the hCAP-18 in the exocytosed material was cleaved (Figure 4C). Thus, cleavage occurs even after stimulation with weak secretagogues if the cell concentration is high enough, indicating that hCAP-18 cleavage may take place during the accumulation of neutrophils in acute inflammation.

**Cleavage experiments with serine proteases**

Immunoblotting of TCA-precipitated cells showed that hCAP-18 exists intracellularly as a holoprotein, as previously described,17 indicating that cleavage of hCAP-18 is performed by a protease not present in the same subcellular compartment as hCAP-18. Thus, it seemed likely that hCAP-18 was cleaved by a serine protease from azurophil granules, as described for bovine and porcine cathelidins.10,11 Incubation with azurophil granule proteins resulted in the cleavage of hCAP-18 (Figure 5, lane b), which could be inhibited.

---

**Table 1. Degranulation of hCAP-18 into the phagolysosome**

<table>
<thead>
<tr>
<th>Donor</th>
<th>Total labeled hCAP-18 (micrograph)</th>
<th>hCAP-18 labeled in granules %</th>
<th>hCAP-18 labeled in phagolysosomes %</th>
<th>Labeled hCAP-18 in phagolysosomes (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Donor 1</td>
<td>1</td>
<td>202</td>
<td>149</td>
<td>53</td>
</tr>
<tr>
<td></td>
<td>2</td>
<td>218</td>
<td>35</td>
<td>183</td>
</tr>
<tr>
<td></td>
<td>3</td>
<td>140</td>
<td>83</td>
<td>57</td>
</tr>
<tr>
<td></td>
<td>4</td>
<td>259</td>
<td>97</td>
<td>162</td>
</tr>
<tr>
<td>Donor 2</td>
<td>1</td>
<td>188</td>
<td>32</td>
<td>156</td>
</tr>
<tr>
<td></td>
<td>2</td>
<td>90</td>
<td>22</td>
<td>68</td>
</tr>
<tr>
<td></td>
<td>3</td>
<td>87</td>
<td>51</td>
<td>36</td>
</tr>
<tr>
<td></td>
<td>4</td>
<td>196</td>
<td>72</td>
<td>124</td>
</tr>
<tr>
<td></td>
<td>5</td>
<td>94</td>
<td>31</td>
<td>63</td>
</tr>
</tbody>
</table>

Degranulation of hCAP-18 into the phagolysosome in exudate neutrophils from skin chamber stimulated to phagocytosis by latex beads. Immunogold-labeled hCAP-18 present in granules and phagolysosomes were counted to determine the degree of degranulation of hCAP-18 into the phagolysosome. Labeled hCAP-18 was counted from 2 donors. Each micrograph represents a different cell.
Isolated neutrophils were incubated with or without stimulus. Exocytosis of granule proteins was determined by ELISA measurements. MPO was chosen as a marker for azurophil granules, hCAP-18 for specific granules, and gelatinase for gelatinase granules. Exocytosis is expressed as percentage of total amount in the cells and medium. Absolute concentrations (ng/mL) of MPO and hCAP-18 are given in parentheses. It should be noted that although the release of MPO from ionomycin-stimulated exudate neutrophils was lower in terms of percentage of total amount than that from exudate cells stimulated with latex beads, the release of MPO was highest in the ionomycin-stimulated cells in terms of absolute concentration of released MPO.

MPO indicates myeloperoxidase; fMLP, formyl methionyleucylphenylalanine; ELISA, enzyme-linked immunosorbent assay.

Table 2. Exocytosis of granule constituents in response to stimulation

<table>
<thead>
<tr>
<th></th>
<th>Control neutrophils</th>
<th>Exudate neutrophils</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>MPO</td>
<td>hCAP-18</td>
</tr>
<tr>
<td>No addition</td>
<td>0.8 (34)</td>
<td>0.9 (29)</td>
</tr>
<tr>
<td>fMLP (10^{-8} M)</td>
<td>2.3 (66)</td>
<td>5.2 (153)</td>
</tr>
<tr>
<td>Immunoglobulin-coated latex beads</td>
<td>14.3 (354)</td>
<td>10.4 (272)</td>
</tr>
<tr>
<td>Ionomycin (1 μM)</td>
<td>34.9 (924)</td>
<td>64.3 (2415)</td>
</tr>
</tbody>
</table>

Isolated neutrophils were incubated with or without stimulus. Exocytosis of granule proteins was determined by ELISA measurements. MPO was chosen as a marker for azurophil granules, hCAP-18 for specific granules, and gelatinase for gelatinase granules. Exocytosis is expressed as percentage of total amount in the cells and medium. Absolute concentrations (ng/mL) of MPO and hCAP-18 are given in parentheses. It should be noted that although the release of MPO from ionomycin-stimulated exudate neutrophils was lower in terms of percentage of total amount than that from exudate cells stimulated with latex beads, the release of MPO was highest in the ionomycin-stimulated cells in terms of absolute concentration of released MPO.

MPO indicates myeloperoxidase; fMLP, formyl methionyleucylphenylalanine; ELISA, enzyme-linked immunosorbent assay.

Figure 4. Immunoblotting of exocytosed material. After stimulation, the neutrophils were pelleted and the supernatant containing the exocytosed material was analyzed by SDS-PAGE and immunoblotting with anti-hCAP-18 antibodies. (A) Exocytosed material from neutrophils harvested from skin windows (10^7 cells/mL), unstimulated cells (lane a) or cells stimulated with fMLP (lane b), IgG-coated latex beads (lane c), or ionomycin (lane d). (B) Exocytosed material from neutrophils isolated from peripheral blood (10^7 cells/mL), unstimulated cells (lane a) or cells stimulated with fMLP (lane b), IgG-coated latex beads (lane c), or ionomycin (lane d). (C) Exocytosed material from fMLP-stimulated neutrophils (3 x 10^7 cells/mL) from peripheral blood.

Figure 5. Immunoblotting of hCAP-18 after incubation with azurophil granule proteins. Purified hCAP-18 was incubated with azurophil granule proteins. Samples were run on SDS-PAGE followed by immunoblotting with anti-hCAP-18 antibodies. Purified hCAP-18 (lane a) incubated with azurophil granule proteins (lanes b-d) and phenylmethylsulfonyl fluoride (lane c) or aprotnin (lane d).
addition of CMK (lane c) but not by chymostatin (lane d) or SLPI (lane e). This resulted in cleavage of hCAP-18 (lane b). This cleavage was inhibited by the antibodies. Purified hCAP-18 (lane a) incubated with exocytosed material (lanes b-e).

Samples were run on SDS-PAGE followed by immunoblotting with anti–hCAP-18 antibody. Lane a, purified hCAP-18; lane b, exocytosed material from ionomycin-stimulated neutrophils; lane c, purified hCAP-18 incubated with azurophil granule proteins; lane d, elastase; lane e, cathepsin G; lane f, proteinase 3; lane g, with exocytosed material from ionomycin-stimulated neutrophils after depletion of the endogenous hCAP-18.

(Figure 8C, lane b) was totally inhibited by CMK but not by chymostatin or SLPI (Figure 8C, lanes c-e).

Thus, both the cleavage pattern of hCAP-18 and the results of the inhibition experiments in the exocytosed material are similar to those obtained with purified proteinase 3. To validate the experiments with exocytosed material, the serine proteases were quantitated by ELISA. The removal of hCAP-18 by affinity chromatography did not increase the concentration of proteinase 3 relative to the concentrations of elastase and cathepsin G (data not shown).

Proteinase 3 was then immunoprecipitated from the exocytosed material before incubation with hCAP-18. Immunoprecipitation with preimmune rabbit antibodies, antielastase antibodies, or anti–cathepsin G antibodies did not inhibit the cleavage of hCAP-18 (Figure 9, lanes b-d) in the exocytosed material, whereas there was no cleavage of hCAP-18 after immunoprecipitation of proteinase 3 (Figure 9, lane e). Measurements in the supernatants after immunoprecipitation showed specific immunoprecipitation of proteinase 3 but no precipitation of elastase or cathepsin G after immunoprecipitation of proteinase 3. Proteinase 3 was not precipitated by antielastase or anti–cathepsin G antibodies (data not shown). The specificity of the anti–proteinase 3 antibodies was validated by immunoblotting. Before immunoblotting with anti–proteinase 3 antibodies, 1.25 μg purified elastase, cathepsin G, and proteinase 3 were run in separate lanes on SDS-PAGE. Reactivity was found only in the lane with proteinase 3 (data not shown). Thus, proteinase 3 was solely responsible for the cleavage of hCAP-18 in the exocytosed material.

Because of the in vitro activity of elastase and cathepsin G toward hCAP-18, we examined whether these proteases were inhibited in vivo after exocytosis by 2 inhibitors reported to be exocytosed from human neutrophils.

SLPI is reported to be a major protein in the neutrophil cytosol and to be exocytosed from human neutrophils. It inhibits elastase and cathepsin G but not proteinase 3. Thus, exocytosed SLPI could prevent the cleavage of hCAP-18 by elastase or cathepsin G in the exocytosed material from neutrophils. However, we were not able to detect any significant amounts of SLPI in unperturbed neutrophils or in the exocytosed material (O.E.S., N.B., P.S.H., unpublished observation, July 1999).

α/2-Antitrypsin is expressed in neutrophils, and the association constant for α/2-antitrypsin and proteinase 3 is one order of magnitude less than that between elastase and α/2-antitrypsin. By immunoblotting and ELISA, we found that α/2-antitrypsin was...
present in the exocytosed material from neutrophils and that \( \alpha_1 \)-antitrypsin could inhibit the cleavage of hCAP-18 by all 3 serine proteases (data not shown). In immunoprecipitation experiments with exocytosed material from neutrophils, none of the 3 serine proteases—elastase, cathepsin G, or proteinase 3—were co-precipitated when \( \alpha_1 \)-antitrypsin was immunoprecipitated. Furthermore, in gel filtration experiments with exocytosed material, \( \alpha_1 \)-antitrypsin eluted as free monomeric protein and did not co-localize with any of the 3 serine proteases (data not shown). Thus, the lack of in vivo activity of elastase and cathepsin G toward hCAP-18 was not due to the inhibition by SLPI or \( \alpha_1 \)-antitrypsin.

The activities of elastase and cathepsin G were then measured in the exocytosed material from neutrophils (5 \( \times \) 10^6 cells/mL) using specific nitroanilide substrates. These experiments were performed in the presence and absence of SLPI to validate that the measured activity was not caused by proteinase 3. Absorbance measured in the presence of the elastase substrate was 3.23 compared to 0.43 when SLPI was added before incubation with the substrate; the corresponding values in the experiment with cathepsin C substrate were 1.42 and 0.26. Measured activities in these experiments were greater than those necessary in the in vitro experiments for the cleavage of hCAP-18 by isolated elastase or cathepsin G. Thus, both elastase and cathepsin G are present as active enzymes in the exocytosed material from neutrophils.

Identification of the C-terminal fragments after cleavage of hCAP-18

To further validate that LL-37 was liberated by proteinase 3–mediated cleavage of hCAP-18, purified hCAP-18 was cleaved by incubation with proteinase 3. The sample was run on SDS-PAGE and blotted to a PVDF membrane, and the low-molecular-mass fragment was analyzed by N-terminal amino acid sequencing of the first 10 residues. These were identified as (L)LGDFFRKSK, consistent with LL-37. Because of contamination, the identity of the first residue could not be unequivocally determined.

Influence of binding to lipoproteins

We have previously shown that hCAP-18 circulates in plasma in a high concentration bound to lipoproteins. We therefore investigated whether lipoprotein-bound hCAP-18 was susceptible to cleavage by proteinase 3. Plasma was incubated with purified hCAP-18 and was subjected to gel filtration. After gel filtration, the peak fraction of hCAP-18 bound to lipoproteins of very low density and low density was incubated with proteinase 3. The lipoprotein-bound hCAP-18 was still susceptible to cleavage by proteinase 3 (Figure 10). Thus, the association to lipoproteins does not prevent the cleavage of hCAP-18.

Discussion

The antibacterial peptide LL-37 is cleaved from the human cathelicidin hCAP-18 between an alanyl and a leucyl residue. This site differs from the cleavage sites in the bovine and porcine cathelicidins, which are cleaved by elastase at elastase-cleavage sites (Figure 1). Most notably, the basic arginyl residue after the cleavage site is substituted with the small aliphatic leucyl residue, and the traditional valyl residue just before the cleavage site is substituted with an alanyl residue. Leukocyte elastase prefers to cleave at a valyl rather than at an alanyl residue. In contrast to the porcine cathelicidins, not all the bovine cathelicidins contain a valyl residue at the putative cleavage site. Thus, it remains to be seen whether some of the bovine cathelicidins are cleaved by proteases other than elastase.

In mice and rabbits, the putative cleavage sites of the cathelicidins do not resemble those in human, porcine, or bovine cathelicidins. The specific proteases responsible for cleavage of these cathelicidins remain to be characterized.

Cathelicidin genes are composed of 4 exons and 3 introns. There is great similarity between the first 3 exons encoding the conserved cathelin part between different cathelicidins but no homology in the fourth exon encoding the active antimicrobial domain and the putative cleavage site. The specific proteases responsible for cleavage of hCAP-18 by proteinase 3 demonstrates that the cleavage site is a functional variable part of the cathelicidins, together with the antimicrobial domain, and that the members of the cathelin family are activated by different proteases in related species. Thus, during evolution the variable biologic functions of the cathelicidins have been changed solely by alterations in the fourth exon.

The 3 known serine proteases in azurophil granules—elastase, cathepsin G, and proteinase 3—cleave many of the same substrates, and hCAP-18 was susceptible to cleavage by all 3 serine proteases in vitro. However, proteinase 3 was found to be solely responsible for the cleavage of hCAP-18 after exocytosis, even though all 3 serine proteases were found in the exocytosed material. This was clearly demonstrated by the fact that the cleavage of hCAP-18 was totally abolished after specific immunoprecipitation of proteinase 3 from the exocytosed material and that immunoblotting with the monoclonal anti–LL-37 antibody showed a cleavage pattern of hCAP-18 after exocytosis consistent only with cleavage by proteinase 3. Both elastase and cathepsin G were found in the exocytosed material, and both enzymes were found to be active. Thus, in a biologic setting, hCAP-18 is a specific substrate for proteinase 3. Interestingly, elastase, cathepsin G, and proteinase 3 also have well-documented in vitro affinity for \( \alpha_1 \)-antitrypsin, but this was not reflected by complex formation in the exocytosed material.

In our in vitro experiments, proteinase 3 did not seem to be as active toward hCAP-18 as elastase is toward bovine and porcine cathelicidins. The interesting question is whether hCAP-18 is processed extracellularly in vivo to a lesser extent by proteinase 3 than the bovine and porcine cathelicidins processed by elastase. Comparison is difficult because of different experimental conditions used (including different types of antibodies). Our polyclonal

![Figure 10. Susceptibility of lipoprotein-bound hCAP-18 to cleavage by proteinase 3](Image)
anti–hCAP-18 antibodies seemed to overestimate the amount of holoprotein, and the monoclonal anti–LL-37 seemed to overestimate the amount of LL-37. However, we have previously blocked the binding of the polyclonal antibodies to the cathelin part of hCAP-18 by adding recombinant cathelin to the primary antibodies; this is probably the best way to estimate the amount of LL-37 compared to holoprotein. In an experiment in which $1.4 \times 10^7$ neutrophils/mL was stimulated with ionomicyn, we estimated that approximately 95% of the holoprotein was processed to LL-37. Even though hCAP-18 seemed to be activated extracellularly to a lesser extent than the bovine and porcine cathelicidins in vivo, the secreted protein 3 in neutrophils was processed extracellularly.

Cleavage by proteinase 3 may be functionally significant for the hCAP-18 expressed in nonhematopoietic tissues, such as lung, skin, and epididymis. Pulmonary monocytes from patients with cystic fibrosis express proteinase 3, and the levels of proteinase 3 activity are greater than those of elastase in the sputum from patients with cystic fibrosis who have chronic lung infections. SLPI is assumed to play an important role in the protection against elastase in the sputum. Nevertheless, additional experiments are performed with serum-treated zymosan particles with similar results. We cannot completely rule out that small undetectable amounts of LL-37 are generated in the phagolysosome, but our data do show that phagocytosis, during which specific and azurophil granule proteases fuse with the phagolysosome, is insufficient for the generation of significant amounts of LL-37.

The main function of hCAP-18, therefore, seems to be extracellular, where LL-37 also acts as a chemotactic agent for neutrophils, monocytes, and T cells. In contrast to the bovine cathelicidins it is unknown whether the porcine cathelicidins are processed in the phagolysosome. Extracellular inhibition of elastase in wound fluids from pigs, which prevents activation of the porcine cathelicidins, impairs the clearance of bacteria from the wounds in vivo. Thus, cathelicidins seem to be important mediators of the extracellular antibacterial activity generated by neutrophils.

In summary, we found that the human cathelicidin hCAP-18 is processed extracellularly to the antimicrobial peptide LL-37 by proteinase 3. This is the first detailed description of the generation of a human antimicrobial peptide from a promicrobial protein, and it demonstrates that the generation of active antimicrobial peptides from common proproteins occurs differently in related species.

Acknowledgments

We thank Hanne Kidmose, Allan Kastrup, Hans Janssen, and Nico Ong for their expert technical assistance. We thank Karsten Lollikke, Jack B. Cowland, Kim Theilgaard-Mönh, Malene Bjørgregaard, Daniel Carter, and Lene Udby for critical review of the manuscript, and we thank Veronique Witko-Sarsat for useful discussions.

References


Human cathelicidin, hCAP-18, is processed to the antimicrobial peptide LL-37 by extracellular cleavage with proteinase 3

Ole E. Sørensen, Per Follin, Anders H. Johnsen, Jero Calafat, G. Sandra Tjabringa, Pieter S. Hiemstra and Niels Borregaard